抗柯注射液对柯萨奇B病毒性心肌炎和扩张型心肌病持续感染干预的实验研究  

A study of virus persistent infection and "SFA"infusion intervention in CoxB viral myocarditis and cardiomyopathy

作　　者：陈曙霞[1] 谢龙山[1] 刘晶星[2] 马睿[1] 徐欣辉[1] 陈美芳[1] 钱富荣[1] 姚季生[2] 

机构地区：[1]上海第二医科大学附属仁济医院心内科,上海200001 [2]上海第二医科大学基础医学院

出　　处：《临床心血管病杂志》2003年第4期222-224,共3页Journal of Clinical Cardiology

基　　金：国家自然科学基金资助课题 (No .395 70 314);上海市科委资助项目(No .994 3192 2 3)

摘　　要：目的 :研究柯萨奇B病毒性心肌炎 (VMC)、扩张型心肌病 (DCM )中病毒持续感染与中药干预作用。方法 :①通过急慢性VMC动物模型 ,用定量多聚酶链反应测脾脏白细胞 (WBC)中以及心肌匀浆中的柯萨奇B病毒核糖核酸 (CBV RNA) ,观察其病毒持续状态 ,以明确病毒持续感染与DCM的意义 ;②观察苦参中抗柯萨奇B病毒的有效成分 (SFA)干预价值。结果 :在急性VMC模型中 ,10mg·kg-1·d-1、15mg·kg-1·d-1、2 0mg·kg-1·d-1SFA分别能清除CBV RNA达 6 7.5 8%、77.0 0 %及 92 .88%。在慢性 (2 70d)VMC动物模型脾脏WBC及心肌匀浆中定量检测的结果均证明有持续感染的存在。用 2 0mg·kg-1·d-1SFA治疗后 ,在心肌匀浆中CBV RNA的清除率为 92 .77% ,脾脏中CBV RNA的清除率为 89.0 4 %。结论 :DCM与病毒持续感染有关 ,SFA能清除CBV RNA ,其清除率与剂量有关 ,并见明显减少病变心肌的病理变化。Objective:To study virus persistent infection and SFA infusion in CoxB viral myocarditis and cardiomyopathy.Methods:①Using quantitative RT PCR technique to detect CBV RNA in spleen white cell and myocardial emulsion of acute and chronic virus infected animal model, to identify the persistent virus infection; ②To observe the clinical value for CBV RNA clearance that intervened by SFA drug.Results:In acute animal model 10 mg·kg -1 ·d -1 , 15 mg·kg -1 ·d -1 , 20 mg·kg -1 ·d -1 SFA could clearant CBV RNA 67.58 %, 77.00 % and 92.88 % individually. In chronic viral animal model (270 days), using quantitative technique to detect CBV RNA in spleen WBC and heart emulsion, all were identified persistent positive results, after SFA admited, the clearance of CBV RNA in heart emulsion was 92.77 %, and the clearance in spleen WBC was 89.04 %.Conclusion:Dilated cardiomyopathy may be induced by viral persistent infections, SFA can clear CBV RNA. The clearant rate depend upon the dorsage of SFA, also can decrease the cardiac pathologic change.

关 键 词：病毒性心肌炎 扩张型心肌病 柯萨奇B病毒 抗病毒药 

分 类 号：R542.2[医药卫生—心血管疾病]